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Abstract 
Purpose: To develop and validate a simple, rapid, sensitive and specific ultraperformance liquid 
chromatography mass spectrometry method for the quantification of the angiotensin II receptor 
antagonist, telmisartan (TEL), in human plasma.  
Methods: After simple protein precipitation using acetonitrile and methanol, TEL and internal standard 
(IS) abiraterone were separated on Acquity UPLC BEHTM C18 column (50 x 2.1 mm, i.d. 1.7 µm, 
Waters, USA) using a mobile phase consisting of acetonitrile: 8 mM ammonium acetate containing 0.15 
% formic acid (v/v) (70:30) pumped at a flow rate of 0.3 mL/min and detected by tandem mass 
spectrometry with positive ion mode. The ion transitions recorded in multiple reaction monitoring mode 
were m/z 515.27→276.13 for telmisartan and m/z 350.1 > 156.0 for internal standard, abiraterone.  
Results: The assay exhibited a linear dynamic range of 1 – 200 ng/mL for telmisartan in human plasma 
with good correlation coefficient (0.995) and limit of quantitation of 1 ng/mL. The relative standard 
deviation for the intra- and inter-assay precision was between 0.75-11.50 
Conclusion: The developed UPLC-MS/MS method is simple, rapid and highly sensitive, and should 
thus be suitable for pharmacokinetic and toxicokinetic studies in both animals and humans. 
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yl)methyl)-biphenyl-2-carboxylic acid) is an 
angiotensin II receptor antagonist widely used in 
the treatment of hypertension and heart failure 
(Figure 1). It undergoes minimal 
biotransformation in the liver to form the inactive 
telmisartan 1-o-acylglucuronide as its principal 
metabolite. The long half-life and selectivity of 
telmisartan for angiotensin II receptors allows 
once daily dosing with minimal side effects [1,2]. 
There are different mechanisms: increasing the 
activity of the sympathetic nervous system, 
causing a boosted sodium revertive resorption in 
the kidneys and promotion of the secretion of 
aldosterone in the adrenal glands [3]. The most 
recent clinical trials demonstrated that 
telmisartan also has preventive roles against 
ischemic heart diseases in diabetic patients with 
a similar potency to angiotensin converting 
enzyme inhibitor [4]. Several studies recently 
suggest that the effects of telmisartan are 
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mediated via not only blockade of AT1R but also 
activation of peroxisome proliferators-activated 
receptor (PPAR)-γ [5]. 
 
 
Figure 1: Chemical structure of telmisartan [A] and 
abiraterone (IS) [B]  
 
The literature reveals that there are a plethora of 
analytical methods reported for the quantitative 
determination of TEL in bulk, pharmaceutical 
formulations and biomatrices mainly based on 
high performance-liquid chromatography (HPLC) 
[6-10] and liquid chromatography-tandem mass 
spectrometry (LC/MS/MS) [11-13]. Other 
methods developed for the determination of 
telmisartan include immunoassay [14]. In 
general, immunoassays lack specificity and 
cannot distinguish multiple analytes or active 
metabolites or degradation products from the 
parent compound. Although HPLC–MS/MS 
method can provide excellent sensitivity, 
however, UPLC-MS/MS provide even more 
significant reduction in analysis time and solvent 
consumption.   The reported HPLC methods 
used column switching or tedious and expensive 
solid phase extraction methods or longer run 
time.  
 
UPLC is a new category of separation science 
which builds upon well-established principles of 
liquid chromatography, using sub-2 µm porous 
particles. These particles operate at elevated 
mobile phase linear velocities to produce 
significant reductions in separation time and 
solvent consumption. Literature indicates that a 
UPLC system allows approximately nine fold 
decreases in analysis time as compared to the 
conventional high-performance (HP) LC system 
using 5 µm particle size analytical columns, and 
approximately threefold decrease in analysis 
time in comparison with 3 µm particle size 
analytical columns without compromise on 
overall separation [15-21].  
 
The objective of the present study was to 
develop and validate an UPLC method coupled 
with tandem mass spectrometry (UPLC-MS/MS) 





TEL was obtained from AK Scientific Inc. (CA, 
USA). Abiraterone was obtained from Selleck 
Chem in Houston, TX, USA. Human plasma was 
obtained from normal healthy volunteers at King 
Khalid University Hospital (Riyadh, Saudi 
Arabia), and the ethical approval of the study 
was obtained from the institutional review board 
of the King Khalid University Hospital. The 
samples were kept frozen at -20 ºC until 
analysis. HPLC-grade acetonitrile, methanol and 
ammonium acetate were obtained from Winlab 
Laboratory, UK. Formic acid was obtained from 
BDH Laboratory, UK. All other reagents were of 
analytical grade unless stated otherwise. All 
aqueous solutions was prepared using water that 
was purified using Milli-QR Gradient A10R 
(Millipore, Moscheim Cedex, France) having pore 
size 0.22 µm.  
 
Apparatus and operating condition 
 
Liquid chromatography  
 
The UPLC system included quaternary solvent 
manager, a binary pump, degasser, autosampler 
with an injection loop of 10 µL and a column 
heater-cooler. The separation was performed on 
Acquity UPLC BEHTM C18 column (50  2.1 mm, 
i.d., 1.7 µm, Waters, USA) maintained at 25 °C. 
The mobile phase was composed of acetonitrile: 
8 mM ammonium acetate containing 0.15 % 
formic acid (v/v) (70:30) pumped at a flow rate of 
0.3 mL/min. The injection volume was 5 µL in 
partial loop mode and the temperature of the 
autosampler was kept at 8 °C. 
 
Mass spectrometric conditions 
 
Waters Acquity liquid chromatography system 
coupled with a Waters TQD triple quadrupole 
mass spectrometer was used (Waters, Milford, 
USA). Mass spectrometric detection was carried 
out using an electrospray interface (ESI) 
operated in the positive ionization mode with 
multiple reaction monitoring (MRM) for both TEL 
and IS. Nitrogen was used as a desolvating gas 
at a flow rate of 500 L/h. The desolvating 
temperature was set at 450 °C and the source 
temperature was set at 150 °C. The collision gas 
(argon) flow was set at 0.1 mL/min. The capillary 
voltage was set at 3.50 kV. The MS analyzer 
parameters were as follows: LM1 and HM1 
resolution 12.0 and 12.0; ion energy 1, 1.0 V; 
LM2 and HM2 resolution 14.0 and 14.0 
respectively, ion energy 2, 0.1 V, dwell time, 
0.146s. The cone voltage and collision energy 
were optimized in case of each analyte so as to 
maximize the signal corresponding to the major 
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transition observed in the MS/MS spectra, 
following the fragmentation of the [M+H]+ ions 
corresponding to the selected compounds. Mass 
resolution is automatically adjusted by intellistart 
software embedded in the Mass Lynx software to 
desired resolution. Mass Lynx software (Version 
4.1, SCN 805) was used to control the UPLC-
MS/MS system as well as for data acquisition 
and processing. 
 
Calibration standards and quality control 
samples 
 
Standard stock solutions of TEL and abiraterone 
(IS), respectively, were prepared by dissolving 
the compounds in methanol, to give a final 
concentration of 1 mg/mL. The 1 mg/mL stock 
solution of TEL was serially diluted to prepare 
working solutions in the required concentration 
range with diluent methanol–water (50:50, v/v). 
The calibration standards and quality control 
(QC) samples were prepared by spiking (5 % of 
the total plasma volume) with working solutions 
yielding concentration range from 1 to 200 ng/mL 
for TEL. The final concentrations for each analyte 
were prepared to be 1, 2, 4, 8, 16, 30, 50, 90, 
100, 200 ng/mL. QC stock solutions for TEL were 
prepared separately in methanol–water (50:50, 
v/v). QC samples at four different concentrations  
levels: 1 ng/mL lower limit of quantitation 
(LLOQ), 2 ng/mL low quality control (LQC) (LQC, 
within three times of the LLOQ), 80 ng/mL middle 
quality control (MQC) and 160 ng/mL high quality 
control (HQC) were prepared in a similar manner 
as the calibration standards. Spiked plasma 
calibration standards and quality control samples 
were kept at −80 oC until assayed or used for 
validating the assay procedures. The IS working 
solution (1 µg/mL) for routine use was prepared 
by diluting the abiraterone stock solution in 
methanol and kept in refrigerator for storage. 
Plasma blank: 200 μL of plasma was spiked with 
20 μL of methanol–water (50:50, v/v). Plasma 
blank with internal standard: 200 μL of plasma 
was spiked with 10 μL of methanol–water (50:50, 




A simple protein precipitation method was used 
to extract telmisartan and the internal standard. 
Plasma samples stored at around -80 oC were 
thawed, left for 1 hour and vortexed for 30 sec on 
room temperature before extraction to ensure 
homogeneity.  To 200 µL of plasma sample, 10 
µL (1 µg/mL) of IS was added.  The samples 
were vortex mixed for about 30 s and then 150 
µL of methanol was added to it and vortex mixed 
again for another 30 seconds. After vortex mixing 
further 500 µL of acetonitrile was added to the 
sample. The samples were again vortex mixed 
gently for 1.5 min and the supernatant was 
separated after centrifugation at 15000 g for 10 
min and evaporated to dryness under a gentle 
stream of nitrogen at 40 ºC. The residue was 
reconstituted with 200 µL of mobile phase 
methanol–water (50:50, v/v) and transferred to 
UPLC vials. 5 µL volumes (in partial loop with 
needle over fill mode) of the sample were 
subjected to the analysis by UPLC–MS/MS. 
 
Bioanalytical method validation 
 
A full method validation was performed according 
to guidelines set by the United States Food and 
Drug Administration (US-FDA) and European 
Medicines Agency (EMEA) guidelines [22,23].  
 
Selectivity and specificity  
 
The selectivity of the method towards 
endogenous plasma matrix components, 
metabolites and component medications was 
assessed in human blank plasma. Among the 
analyzed plasma batches, plasma batch showing 
no or minimal interference at the retention time of 
analytes and internal standards was selected. 
They were processed and analyzed using the 
proposed extraction protocol spiked with 
standard TEL at lower limit of quantification 
(LLOQ) level (1 ng/mL) and IS 50 ng /mL. 
 
Linearity and standard curve  
 
The linearity of the method was determined by 
analysis of standard plots associated with ten 
point standard calibration curve (1 - 200 ng/mL). 
Calibration curves from accepted three precision 
and accuracy batches were used to establish 
linearity.  Curves were best fitted using a least 
square linear regression model y = mx+ b, 
weighted by 1/x2, in which y is the peak area 
ratio, m is slope of the calibration curve, b is the 
y-axis intercept of the calibration curve and x is 
the analyte (TEL) concentration. Back-
calculations were made from these curves to 
determine the concentration of TEL in each 
calibration standards and the resulting calculated 
parameters were used to determine 
concentrations of analyte in quality control 
samples. The determination coefficient r2 > 0.996 
was desirable for all the calibration curves. The 
lowest standard on the calibration curve was to 
be accepted as the lower limit of quantification 
LLOQ.  
 
Precision and accuracy  
 
Intra- and inter-day accuracies expressed as a 
percentage of deviation from the respective 
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nominal value. The precision of the assay was 
measured by the percent coefficient of variation 
(% CV) at four concentrations in human plasma. 
Intra-day precision and accuracy were assessed 
by analyzing six replicates of the quality control 
samples at four levels (quality control) during a 
single analytical run. The inter-day precision and 
accuracy were assessed by analyzing 18 
replicates of the quality control samples at each 
level through three precision and accuracy 
batches runs on 3 consecutive validation days.  
 
Extraction recovery and matrix effect 
 
To investigate extraction recovery, a set of 
samples (n = 6 at each low, medium, and high 
concentration levels in unique lots of plasma) 
was prepared by spiking telmisartan into plasma 
at 2, 80, and 160 ng/mL, respectively. Each of 
the samples were processed as per the 
procedure described previously. A second set of 
plasma samples was processed and spiked post-
extraction with the same concentrations of 
telmisartan and IS that actually existed in the 
pre-extraction spiked samples. Extraction 
recovery for each analyte was determined by 
calculating the ratios of the raw peak areas of the 
pre-extraction spiked samples to those of the 
samples spiked after extraction. The matrix effect 
was evaluated by analyzing MQC sample. 
 
Stability and dilution integrity evaluation  
 
Stability of TEL in plasma was assessed by 
analyzing six replicates of QC samples at low 
and high concentrations under a variety of 
storage and processing conditions. Six aliquots 
of each low and high concentration quality 
control samples were taken to evaluate the 
bench top stability (short term stability), freeze 
thaw stability, auto sampler storage stability and 
long term stability. Bench-top stability was 
assessed after exposure of the plasma samples 
to room temperature for ∼ 6 h, which exceeds 
the residence time of the sample processing 
procedures. The freeze–thaw stability was 
evaluated after undergoing three freeze (at 
around −80 oC) thaw (room temperature) cycles. 
The autosampler storage stability was 
determined by storing the reconstituted QC 
samples for ∼ 48 h under autosampler condition 
(maintained at 8 oC) before being analyzed. 
Long-term stability was assessed after storage of 
the test samples at around −80 oC for 60 days. 
The working solutions and stock solutions of TEL 
and the IS were also evaluated for stability at 
room temperature for 24 h and at refrigerator 
temperature (below 10 oC) for 25 days. All 
stability exercises were performed against freshly 
spiked calibration standards. The dilution 
integrity experiment was intended to validate the 
dilution test to be carried out on higher analyte 
concentrations (above ULOQ), which may be 





The best chromatographic conditions were 
achieved with mobile phase comprising 
acetonitrile: 8 mM ammonium acetate containing 
0.15 % formic acid (v/v) (70:30) pumped at a flow 
rate of 0.30 mL/min, on a C18 column (50  2.1 
mm i.d., 1.7 µm). The selected conditions were 
found to be suitable for the determination of 
electrospray response for TEL and IS (Figure 2). 
The method was found to be linear from 1 to 200 
ng/mL for TEL in human plasma. The 
determination coefficients (r2) were consistently 
greater than 0.995 during the course of 
validation. The lower limit of quantification for this 
assay was 1 ng/mL in plasma. Table 1 
summarizes the inter- and intra-day precision 
and accuracy values for QC samples. The 
coefficient of variation values of both intra- and 
inter- day results of plasma were 3.80 – 11.50 % 
and 0.75 – 2.74 %, respectively. TEL showed an 
average (n=6) matrix factor of 99.12 % at MQC 
level with a CV of 4.11 %. 
  
The stability results, summarized in Table 2, 
showed that TEL spiked into human plasma was 
stable for at least 6 h at room temperature, for at 
least 48 h in final extract at 8 oC under 
autosampler storage condition, for 25 days at 
around −80 oC, and during three freeze–thaw 
cycles when stored at around −80 oC and thawed 
to room temperature. The stock solutions and 
working standard of TEL and IS were stable for 
25 days at refrigerator temperature (below 10 oC) 
and at least for 24 h at room temperature. In 
dilution integrity study, accuracy of the 2- and 4-
fold diluted samples was 97.27 and 97.82 % of 
the nominal concentration for TEL. At three QC 
concentration levels (2, 80 and 160 ng/mL), the 
percent extraction recoveries (mean ± SD) of 
TEL obtained are given in Table 3. The mean 
extraction recovery for TEL was 82.12 ± 2.38 %, 
and for the IS abiraterone at the concentration 
employed, it was 88.69  ±  4.33 %. 
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Figure 2: (A) Representative chromatograms of blank, [B] Representative chromatograms of HQC of TEL in 
human plasma  
 
Table 1: Intra- and inter-day precision and accuracy of TEL in human plasma 
 
Nominal conc. 
(ng/mL) Run Human plasma     
    Measured conc. (ng/mL ± SD) Precision (RSD) 
Intraday variation (n=6 at each concentration) 
1 1 1.00 ± 0.06 6.77 
 2 0.95 ± 0.10 11.50 
 3 0.99 ± 0.09 9.50 2 1 2.04 ± 0.15 7.36 
 2 1.97 ± 0.14 7.48 
 3 2.08 ± 0.14 6.76 80 1 82.51 ± 4.54 5.50 
 2 80.15 ± 6.16 7.76 
 3 81.00 ± 3.90 4.82 160 1 165.91 ± 6.30 3.80 
 2 164.12 ± 6.50 3.96 
 3 163.50 ± 7.09 4.33 
     Interday variation (n = 18, at each concentration) 
1  0.98 ± 0.02 2.56 2  2.03 ± 0.05 2.74 80  81.22 ± 1.19 1.46 160   164.51 ± 1.24 0.75 
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Table 2: Stability and dilution integrity data of TEL in human plasma 
 
Stability  
(n = 6) 
Nominal conc. 
(ng/mL) 
Measured conc. (ng/mL ± 
SD) Precision (RSD) 
Bench top (6 h) 2 2.02  ± 0.15 7.48 
 160 158.29 ± 7.32 4.62 Freeze thaw (3 cycle) 2 2.00  ± 0.12 6.45 
 160 161.67 ± 7.14 4.41 Auto sampler (48 h) 2 1.97  ± 0.11 7.15 
 160 166.32 ± 6.48 4.02 25 days at   ̶80◦C 2 1.96  ± 0.16 5.89 
 160 159.02  ± 5.68 3.97 Dilution integrity 80 77.82 ± 6.36 6.59 
  160 156.52 ± 8.09 4.99 
 
Table 3: Extraction recovery data of TEL (three QC samples) and abiraterone in human plasma 
 
Compound Nominal conc. (ng/mL) Recovery (% ± SD ) 
TEL (analyte) 2 79.58 ± 7.13 
 80 82.47 ± 6.13 
 160 84.31 ± 8.13 
 Mean ± SD 82.12 ± 2.38 




Initial feasibility experiments of various mixture(s) 
of organic solvents such as acetonitrile and 
methanol along with millipore water; both having 
0.1 % formic acid, also these organic solvents 
along with different concentration of  ammonium 
acetate (2 - 15 mM) with altered flow-rates (in the 
range of 0.20 – 0.50 mL/min) was performed to 
optimize an effective chromatographic conditions 
of TEL and IS. UPLC-MS/MS operation 
parameters were carefully optimized for the 
determination of TEL. Analytes were detected by 
tandem mass spectrometry using MRM of 
precursor–product ion transitions with 0.146 s 
dwell time, at m/z 515.27 > 276.13  for TEL and 
m/z 350.1 > 156.0  for IS. A standard solution 
(100 ng/mL) of TEL and the IS were directly 
infused along with the mobile phase into the 
mass spectrometer with ESI as the ionization 
source. The mass spectrometer was tuned 
initially in both positive and negative ionization 
modes for TEL. It was observed that the signal 
intensity of positive ion was much higher than 
that of negative ion. 
  
Parameters, such as capillary and cone voltage, 
desolvation temperature, ESI source temperature 
and flow rate of desolvation gas and cone gas, 
were  optimized to obtain the optimum intensity 
of protonated molecules of TEL and IS for 
quantification. Among the parameters, capillary 
and cone voltage, especially cone voltage, were 
important parameters. The precursor ion 
intensities increased significantly when cone 
voltage was raised gradually. Lastly, analytes 
produced the strongest ion signals when cone 
voltage was set up at 72 V. The cone voltage 
was optimized using cone ramp (0 - 100) V. The 
collision energy was investigated from 2 to 80 eV 
to optimize the response of product ion, and the 
best values were found to be 50 eV for the 
chosen product ions m/z 276.13. For IS, spectra 
at m/z 156.0 was produced at optimum collision 
energy of 48 eV.   
 
Selectivity of the method was assessed by 
comparing the chromatogram of blank plasma 
with the corresponding spiked LLOQ sample. Six 
different batches of blank human plasma were 
tested to identify the peaks due to the possible 
biogenic plasma components. Thus the method 
looks to be selective enough for determination of 
TEL and IS in plasma. The linearity of the 
method was determined by a weighted least 
square regression analysis of standard plot 
associated with a nine-point standard curve. The 
calibration curves were generated by plotting 
area ratio (TEL/IS) as a function of TEL 
concentration. Representative LLOQ was 
sensitive enough to investigate the 
pharmacokinetic behavior of TEL in human 
plasma. These results indicate that the method 
has good precision and accuracy and are within 
the acceptance limit of < 15 % and ± < 15 % for 
precision and accuracy respectively. In this 
study, the matrix effect was evaluated by 
analyzing MQC sample. 
  
The stabilities of TEL were investigated at two 
concentrations of QC samples (low and high 
concentrations) to cover expected conditions 
during analysis, storage and processing of all 
samples, which include the stability data from 
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various stability exercises like in-injector, bench-
top, freeze/thaw and long-term stability tests. 
These results conclude that TEL was stable 
under the set experimental conditions and the 
dilution of the concentrated plasma sample up to 
four times maintains legibility and integrity of TEL 
concentration. This result indicates that the 
extraction efficiency for TEL using protein 
precipitation method was satisfactory, consistent 




This study represents the first report describing 
the determination of TEL in human plasma by 
UPLC-MS/MS method. The developed method is 
simple, economical high-throughput and highly 
sensitive. Run time was only 2.5 min which is 
suitable for high-throughput analysis and 
reduction in the use of organic solvents. The 
proposed method is practical and should suitable 
for pharmacokinetic and toxicokinetic studies of 
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